Abstract Number: 203 • ACR/ARHP Annual Meeting 2016
Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study
Brian W Coburn1,2, Kaleb Michaud3, Debra A Bergman2 and Ted R Mikuls4,5, 1Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 4Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 5Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Allopurinol Dose Escalation and Mortality among Patients with Gout: A National Propensity-Matched Cohort Study Background/Purpose: Numerous epidemiologic studies show that hyperuricemia and gout are associated…Abstract Number: 2356 • ACR/ARHP Annual Meeting 2015
Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…Abstract Number: 2121 • ACR/ARHP Annual Meeting 2014
Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease
Background/Purpose Gout flare prevention relies heavily on urate-lowering therapies (ULT) such as allopurinol (ALP) and febuxostat (FBX) but clinical decision-making in patients with moderate to…
ACR Meeting Abstracts